AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04091074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Half of patients undergoing carotid stenting take ticagrelor+aspirin
Study NCT04091074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Other half ofpatients undergoing carotid stenting take clopidogrel+aspirin
Study NCT04091074 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid stenting
Description: Patients with carotid stenosis will undergo carotid stenting
Study NCT04301778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1. Durvalumab - 1500 mg via IV infusion over 60 minutes (-5/+10 min) on day 1 of each 28-day cycle (every 4 weeks).~2. Drug - 1500mg IV
Study NCT04301778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNDX-6352
Description: 1. SNDX-6352 - 3mg/kg via IV infusion over 30 minutes (-5/+10 min) on days 1 and 15 of each 28-day cycle (every 2 weeks), starting with cycle 2 (not given during cycle 1).~2. Drug - 3mg/kg IV
Study NCT06564441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Survodutide
Description: Survodutide
Study NCT06564441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion
Study NCT06564441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine
Study NCT06564441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam
Study NCT05422326 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N6c on Day 1
Description: MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular (IM) administration, containing 7.5 μg H5N6 hemagglutinin (HA) (A/Guangdong/18SF020/2018 (H5N6)-like) + 0.25 mL MF59 (approximately 0.5 mL total volume)
Study NCT05422326 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N6c on Day 22
Description: MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular (IM) administration, containing 7.5 μg H5N6 HA (A/Guangdong/18SF020/2018 (H5N6)-like) + 0.25 mL MF59 (approximately 0.5 mL total volume) given 3 weeks after the first aH5N6c vaccination
Study NCT05422326 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo on Day 22
Description: Saline placebo (sterile, 0.5 mL) given 3 weeks after the aH5N6c vaccination
Study NCT05156918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will rotate between three exercise machines (randomly assigned rotation order at outset): A Concept C2 rowing machine, a stationary bicycle, and a treadmill. Study participants will use a different machine each day so that they are using each of the three exercise machines once per week. Two treadmills, two bikes, and two rowers are available during each exercise session. Participants will be randomly assigned to one of three machine orders: treadmill-rower-bike, rower-bike-treadmill, or bike-treadmill-rower. We will employ a percent of heart rate protocol as an exercise intensity measure (77-93% of age-adjusted maximum heart rate) rather than a less well-defined maximal effort protocol or rating of perceived exertion scale. For the purposes of this exercise protocol high intensity exercise will be defined as 77-93% of age adjusted maximum heart rate.
Study NCT05156918 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non Exercise
Description: There are no modifications to regular diet or exercise habits for 30 days.
Study NCT05536349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Given by PO
Study NCT05536349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given by (IV) vein
Study NCT05536349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO
Study NCT05536349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Given by PO
Study NCT05536349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Given by PO
Study NCT04871789 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory and instrumental examination
Description: All patients will undergo a comprehensive examination to identify the consequences of COVID-19
Study NCT04468360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-day differential fear conditioning, extinction, and extinction retention testing paradigm
Description: Day 1: Fear acquisition involving the pairing of a brief, noxious but not painful air blast to the neck (unconditioned stimulus; US) to a conditioned stimuli (CS) (Expts. 1 and 2). The CS will be different colored shapes appearing on a computer monitor. An auditory stimulus will serve as the startle probe. Day 2: Either extinction training (Expt. 1) or fear memory reactivation by a single CS+ with no US (Expt. 2) will occur followed by IV Allo vs. IV placebo administration. Day 3: The effects of IV Allo vs. IV placebo (administered on Day 2) on extinction retention (Expt. 1) or reconsolidation blockade (Expt. 2), as well as reinstatement of conditioned fear (Expts. 1 and 2) will be assessed.
Study NCT04468360 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: 3-day differential fear conditioning, extinction, and extinction retention testing paradigm
Description: Day 1: Fear acquisition involving the pairing of a brief, noxious but not painful air blast to the neck (unconditioned stimulus; US) to a conditioned stimuli (CS) (Expts. 1 and 2). The CS will be different colored shapes appearing on a computer monitor. An auditory stimulus will serve as the startle probe. Day 2: Either extinction training (Expt. 1) or fear memory reactivation by a single CS+ with no US (Expt. 2) will occur followed by IV Allo vs. IV placebo administration. Day 3: The effects of IV Allo vs. IV placebo (administered on Day 2) on extinction retention (Expt. 1) or reconsolidation blockade (Expt. 2), as well as reinstatement of conditioned fear (Expts. 1 and 2) will be assessed.
Study NCT04468360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopregnanolone (Allo) with Dexolve in 0.9% saline for injection manufactured by University of California, Davis
Description: Expt. 1 (extinction retention): On Day 2, a 1.7 ug/kg IV bolus of Allo will be administered over 5 minutes at the completion of extinction training and continued as a 5-hour drip to maintain resting plasma Allo levels at \~1500 pg/ml. Expt. 2 (reconsolidation blockade): On Day 2, a 28 ug/kg IV bolus of Allo will be infused over 30 minutes immediately following presentation of a single CS+.
Study NCT04468360 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching IV Placebo
Description: Expt. 1 (extinction retention): On Day 2, a 1.7 ug/kg IV bolus of the matching placebo formulation will be administered over 5 minutes at the completion of extinction training and continued as a 5-hour drip to maintain resting plasma Allo levels at \~1500 pg/ml. Expt. 2 (reconsolidation blockade): On Day 2, a 28 ug/kg IV bolus of the matching placebo formulation will be infused over 30 minutes immediately following presentation of a single CS+.
Study NCT05824026 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Gelling fiber wound dressing with silver
Description: intervention involving a wound dressing with silver
Study NCT05830955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lullaby group
Description: The preterm newborns who are going to listen a live lullaby from their mothers' voice will be the first group (Lullaby group).
Study NCT05830955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast milk group
Description: The preterms in the second group (Breast milk group) are going to smell their mothers' breast milk.
Study NCT05830955 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The preterms in the third group (Control group) are going to recieve rutin nursing care interventions.
Study NCT06580145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-leucine
Description: L-leucine is an essential amino acid used to competitively inhibit kynurenine uptake into the brain via the large neutral amino acid transporter (LAT1).~The proposed dose for L-leucine is 4.31 g/day, administered orally.
Study NCT06580145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-lysine
Description: L-lysine monohydrochloride is also an essential amino acid. It serves as an active comparator to control for general effects on brain protein synthesis and enters the brain through separate cationic amino acid transporters.~The proposed dose for L-lysine is 6 g/day, administered orally
Study NCT05456308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrodistention during cystoscope
Description: Hydrodistention for treatment of interstitial cystitis will be performed. Participants will be randomly selected to one of the arms described. There are three variables that they will be assigned: the pressure of fluid in the bladder that will be filled, the duration of time that the fluid will be held in the bladder, and the number of times the procedure is completed.
Study NCT06495619 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: treatment-as-usual
Description: life style modification intervention for weight loss
Study NCT06495619 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: combined TAU and guided self-help
Description: combined TAU and guided self-help for improving eating behaviors
Study NCT06495619 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: combined TAU, GSH, and biofeedback
Description: combined TAU, GSH, and biofeedback for improving eating behaviors and interoceptive awareness and arousal regulation
Study NCT04526366 — intervention group
Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure
Description: Continuous Positive Airway Pressure device deployed for at least one night synchronously with polysomnography.
Study NCT04526366 — intervention group
Intervention type: DEVICE
Intervention: Polysomnography
Description: Polysomnography deployed for at least one night synchronously with Continuous Positive Airway Pressure.
Study NCT04588961 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trapeziectomy with suspensionplasty
Description: Surgical removal of trapezium bone and ligamentoplasty of first metacarpal bone using abductor pollicis tendon
Study NCT04588961 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Joint alloplasty
Description: Surgical removal of degenerated joint surfaces nad replacement using modern designed prothesis
Study NCT05640349 — intervention group
Intervention type: BIOLOGICAL
Intervention: Positive blood culture
Description: Positive blood culture recorded at the microbiology laboratory of University Hospital of Nic
Study NCT04594031 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ECT-001-CB (UM171-Expanded Cord Blood Transplant)
Description: Single ECT-001-CB transplant (CD34+: 2 to 5.75x10E5/kg, CD3+ >1x10E6/kg)
Study NCT06579716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional balance exercise
Description: All patients in both group received a traditional balance exercise program, 3 sessions per week, for 6 weeks. Each session of exercise comprised 10 min of warm-up, 40min of balance exercise, and 5min of cool down. Warm-up included treadmill walking. Balance exercise comprised two sets of sit to stand, one leg stance, tandem stance and 30 squats. The first set of exercises was performed on a stable surface, whereas the second set of exercises was performed on an unstable surface by using Thera band stability trainer. Each set of each exercise was performed for 3 min, with 1-2 min of rest in between the exercises. Cool-down included deep breathing, abdominal breathing, and mild stretching.
Study NCT06579716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: All patients in both group received a resistance exercise program, 3 sessions per week, for 6 weeks. Each patient was seated in sitting position and the weight sandbags was applied at the dorsum of the foot. The resistance was set to be around 40%-60% of the 1RM. The patient performed the exercise for 3 bouts, every bout 10 repetitions. The one repetition maximum (1RM) was established prior to the training period using the following equation: 1 RM = Weight (kg) X (1 + {0.033 X number of repetitions)}.
Study NCT06579716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Description: Patients were asked to stand barefoot on the vibratory platform with an even distribution of weight on both feet and familiarized with WBV at a lesser frequency and amplitude. Then, they were asked to bend their knee 30º to the vertical; thereafter, to obtain a greater muscular response, WBV training was performed at a frequency of 30 Hz and an amplitude of 2mm. The exercise comprised five bouts of a 30-sec vibration with a 1-min elapse between the bouts.
Study NCT06579716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kineso tape
Description: Kineso tape was applied to dorsiflexors 24 hours a day and was replaced every 5 days for patients who were taped in accordance with Kenzo Kase's Kinesio taping Manual. For taping, each patient's leg was placed in a relaxed position while he sat on a taping table. The skin was to be free of oils and lotions, to avoid anything that might limit the acrylic adhesive's ability to adhere to the skin. So, the subject's skin was cleaned with alcohol prior to tape application. For the Tibialis anterior, tape was measured from the muscle origin to the insertion while the muscle was stretched. The base of the tape was applied to the origin at the lateral condyle and superior 2/3 of anterolateral surface of tibia. Then the subject was asked to stretch the foot into plantar flexion and eversion; taping was then finished toward the insertion at the medial and plantar surface of medial cuneiform and base of the first metatarsal.
Study NCT06089577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor 50 MG
Description: Cangrelor will be administered during PCI
Study NCT06636877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019
Description: One tablet administered alone
Study NCT06636877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1019-2
Description: One tablet administered alone
Study NCT06636877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1019-3
Description: One tablet administered alone
Study NCT05169164 — intervention group
Intervention type: OTHER
Intervention: No intervention, observational
Description: No intervention, observational
Study NCT06278285 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood GLP1
Description: On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with anti-GLP-1 analogues
Study NCT06278285 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood No treated GLP1
Description: On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with patients not treated with anti-GLP-1 analogues) and the presence of fibrosis.
Study NCT06044636 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digi-physical breastfeeding support
Description: * Breastfeeding support after birth is provided via chat~* Extended home visits by a pediatric nurse after discharge from the maternity ward~* Extra support from a lactation counselor when needed after discharge until one year after childbirth
Study NCT04893785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib and Temozolomide
Description: Patients enrolled will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.~Patients will be required to attend clinic on Day 1, Day 8, Day 14 and Day 22 of every 4 week cycle.~Patients will return to clinic at 30 days (+/- 5 days) of their last dose of cabozantinib or temozolomide (whichever is discontinued last), for an end of treatment visit.~Following their end of treatment visit patients will be followed-up 3-monthly during routine clinic appointments to collect data on further anti-cancer treatment and survival. Follow-up will continue until 6 months after the last patient stops study treatment or up to 18 months after the last patient is randomised, whichever is sooner.
Study NCT05756348 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Marathon® XL No Sting Cyanoacrylate Skin Protectant and 3M™ Cavilon™ Advanced Skin Protectant
Description: All participants will receive both device interventions listed above.
Study NCT05004857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Book reading
Description: Prior to the first session, a research assistant will place electrodes on the infant and mother so that they study team can gather autonomic nervous system (ANS) response (sympathetic and parasympathetic) non-invasively using MindWare Portable Lab System (MindWare Technologies, Gahanna, Ohio). These electrodes will remain on the infant and mother throughout each session and be removed via adhesive removing pads following each session's data collection. This will minimize discomfort to both parties secondary to electrode removal and minimize risk of skin irritation by leaving electrodes in place for a prolonged period of time. Additional observational data before and after the reading sessions will be collected by the research assistant, including but not limited to: where the session is conducted (mother's arms, bassinet), activity level, vital signs, and any other observed behaviors throughout the session.
Study NCT06316583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TrP-DN and Acupuncture
Description: Treatment is conducted by pain specialists and acupuncturists, each having over 5 years of relevant work experience. The treatment occurs within the three weeks leading up to menstruation, administered once a week for a total of three sessions. Additionally, participants are to engage in abdominal stretching exercises starting from the treatment day. These exercises are to be done 3-5 times daily, with each session lasting approximately 2 minutes, and this regimen is to continue for one month. If participants experience significant pain during menstruation, they may take NSAIDs orally for symptomatic relief.
Study NCT06316583 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: TrP-DN and Acupuncture
Description: Treatment is conducted by pain specialists and acupuncturists, each having over 5 years of relevant work experience. The treatment occurs within the three weeks leading up to menstruation, administered once a week for a total of three sessions. Additionally, participants are to engage in abdominal stretching exercises starting from the treatment day. These exercises are to be done 3-5 times daily, with each session lasting approximately 2 minutes, and this regimen is to continue for one month. If participants experience significant pain during menstruation, they may take NSAIDs orally for symptomatic relief.
Study NCT06528249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes
Description: Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes
Study NCT04822662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Epilepsy Education Programme
Description: Firstly the Child Introduction Form and Parent Information Form were applied. Then the Child's Attitude Towards Self-Disease Scale, Seizure Self-Efficacy Scale for Children, Quality of Life Scale for Children were filled to children. Nurse-Parent Support Scale were applied to the parents in the Pretest and Post Test data.
Study NCT05633940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation of the service delivery model primary care behavioral health
Description: The research project will study a real-world implementation of PCBH in routine primary care. The implementation is facilitated by a regional implementation group of psychologists with special training in PCBH. The active implementation period for each intervention center is 12 months, where continuous support, materials and training are offered by the implementation group.
Study NCT05679102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5 MG Oral Tablet
Description: one group will be given only Amlodipine 5MG once daily
Study NCT05679102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5 MG / Atorvastatin 10 MG Oral Tablet
Description: one group will be given Amlodipine 5mg plus Atorvastatin 10MG once daily
Study NCT04763837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraureteral stent
Description: This intervention involves the placement of an intraureteral stent, a tube that drains urine from the kidney to the bladder and has a loop of tube only in the kidney and NOT in the bladder. The distal end of the tube will stay in the ureter just proximal to the opening to the bladder.
Study NCT04763837 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Double-J stent
Description: This intervention involves the placement of a conventional double-J stent, a tube that drains urine from the kidney to the bladder and has a loop of tube in both the kidney and in the bladder.